Early-Stage Programs
Given Xenon’s expertise in drug discovery, our efforts are concentrated on the identification of targets where we believe novel modulators could represent significant therapeutic advances.
We intend to leverage our deep ion channel expertise to develop promising drug candidates that target sodium and potassium channels, with a near-term focus on internal development candidates targeting Kv7, Nav1.1 and Nav1.7.
Our goal is to advance multiple candidates into IND-enabling studies in 2025.
A Phase 1 study in healthy adult participants is underway for XEN1120, a Kv7 channel opener in development for pain. Work remains ongoing with additional Kv7 development molecules and chemistries with the hypothesis that Kv7 may have utility in a broad range of therapeutic indications including seizure disorders, pain, and neuropsychiatric disorders, such as MDD and BPD.
A Phase 1 study has been initiated for XEN1701, our lead Nav1.7 development candidate for pain. IND-enabling work remains ongoing for additional Nav1.7 candidates. Nav1.7 is an important pain-related target, based on strong human genetic validation, which may represent a new class of medicines without the limitations of opioids.
